Company profile
Evaxion A/S logo

Evaxion A/S

Pipeline8 assets

  • EVX-01EVX-01 / Personalized neoantigens / Liposomal/peptide personalized cancer vaccine / Cancer
    Advanced melanomaPhase 2
  • EVX-03EVX-03 / Personalized neoantigens and endogenous retrovirus antigens / Targeted DNA personalized cancer vaccine / Cancer
    Solid tumorsPreclinicalCTA/IND ready
  • EVX-04EVX-04 / Tumor-specific antigens derived from endogenous retrovirus elements / DNA off-the-shelf therapeutic cancer vaccine / Cancer
    Acute myeloid leukemiaPreclinicalPlanned first-in-human study
  • EVX-B1EVX-B1 / S. aureus toxins and virulence factors / Protein multi-component prophylactic vaccine / Infectious diseases
    S. aureus skin and soft tissue infectionsPreclinical
  • EVX-B2EVX-B2 / N. gonorrhoeae antigens / Protein multi-component prophylactic vaccine / Infectious diseases
    GonorrheaPreclinical
  • EVX-B2 mRNAEVX-B2 / N. gonorrhoeae antigens / mRNA multi-component prophylactic vaccine / Infectious diseases
    GonorrheaPreclinical
  • EVX-B4EVX-B4 / Group A Streptococcus antigens / Prophylactic vaccine / Infectious diseases
    Group A Streptococcus infectionTarget discovery
  • EVX-V1EVX-V1 / CMV B- and T-cell antigens; pre-fusion glycoprotein B construct / Multi-component prophylactic vaccine / Infectious diseases
    Cytomegalovirus infectionPreclinical

Latest news18 items

All news

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented

Presentation / Abstract • Phase 2ESMO poster presentation Sat, Oct 24, 2026, 12:00 PM CET

Evaxion receives Prix Galien UK Award for Best digital health solution

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.

Evaxion concludes Annual General Meeting

COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company’s offices. The 2025 Annual Report was approved and the Board of

Notice to convene Evaxion’s Annual General Meeting

COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.

Evaxion to present new data at AACR Annual Meeting

Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer)

Presentation / Abstract • Phase 2

Evaxion plans to file 2025 annual report later today

COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today,

Evaxion A/S • Endpoint Arena